SAIBA AG

HARNESSING THE POWER OF VACCINATION

Historically thought of as a weapon to combat infectious disease, we believe vaccination has the potential to revolutionize practically any aspect of health care.

Saiba proprietary technology has enabled scientists to generate a vaccine candidate against COVID-19 with preclinical proof-of-concept

Sa

OUR TECHNOLOGY

We use virally shaped nanoparticles as a scaffold for the generation of tailor-made vaccines. The nanoparticle base of the vaccines tricks the immune system into believing to be under viral attack, causing a strong immune response against the displayed antigen. The technology has been optimized to induce strong immune responses in all individuals, including the more senior citizens.

OUR MISSION

Saiba GmbH develops novel vaccines for unmet medical needs. The vaccines are optimized for chronic diseases with a focus on the elderly and old people. Main areas of development are vaccines against chronic inflammatory diseases, such as psoriasis and multiple sclerosis, as well as Alzheimer`s and Parkinson`s disease. Vaccines against malaria and pandemic flu are additional areas of focus.

salejoo

SAIBA AG

OUR TECHNOLOGY

With the effective control of infectious diseases in many parts of the world, chronic, often non-communicable diseases have become the single largest cause of death and disability.

Treatment of such chronic diseases is expensive and often ineffective. There is therefore a major need for novel treatment modalities to prevent rather than treat chronic diseases and that are available at affordable costs.

Inducing long-lived antibody responses by vaccination against endogenous molecules, which are normally targeted by monoclonal antibodies, represents a promising way to tackle this issue.

We use virally shaped nanoparticles as a scaffold for the generation of tailor-made vaccines. The nanoparticle base of the vaccines tricks the immune system into believing to be under viral attack, causing a strong immune response against the displayed antigen.

Despite effective control of many of the deadly infectious diseases by vaccination, there remains a substantial number of important pathogens for which there exists no effective preventive tool based on immunization.

Modern vaccine design consists of an optimized antigen rendered immunogenic by formulation in adjuvants or presentation on an immunogenic scaffold.

Virus-like particles (VLPs) are the most immunogenic recombinant scaffold for display of antigens with strong Proof-of-Concept (PoC) in man. This technology has been optimized to induce strong immune responses in all individuals, including the more sensitive groups like senior citizens.

Despite effective control of many of the deadly infectious diseases by vaccination, there remains a substantial number of important pathogens for which there exists no effective preventive tool based on immunization.

Modern vaccine design consists of an optimized antigen rendered immunogenic by formulation in adjuvants or presentation on an immunogenic scaffold.

Virus-like particles (VLPs) are the most immunogenic recombinant scaffold for display of antigens with strong Proof-of-Concept (PoC) in man. This technology has been optimized to induce strong immune responses in all individuals, including the more sensitive groups like senior citizens.

SAIBA AG

OUR SERVICES

Saiba can assist you in a number of ways, ranging from strategic planning consultation, to offering of licencing of proprietary technology through to complete development of your project.

Consult

With the experience by world-leading vaccination expert Professor Martin Bachmann on board, Saiba knows about the potentials as well as the pitfalls of translational immunology projects. We can advise you on possibilities, options, and strategies.

License

With a portfolio of intellectual property on a variety of aspects of vaccination and freedom to operate, we are in a position to licence out upstream rights tailored to your application.

Develop

We have a variety of partners who collaborate with Saiba to guide vaccines through early stage of development. Covering all aspects from plan through to proof-of-principle pre-clinical studies, Saiba can guide your project to the point of scale up to GMP-approved manufacture. Saiba have an established network of partnering institutions with a documented track record to deliver all resources required for your project (small scale production / GMP-grade vaccines / pre-clinical testing /regulatory guidance).

OUR PARTNERS

Saiba collaborates with a number of academic and industrial partners on a range of projects. Some of our partners are highlighted below.

SAIBA AG

WHO WE ARE

 

The founder of Saiba GmbH combines unique expertise in biotech, vaccinology and immunology. Saiba GmbH combines unique knowhow from biotech as well as basic research. In addition to key scientific personal, Saiba employs a large academic and pharma network as well as advisors.

PATRIK M. PAULUS, EXECUTIVE CHAIRMAN & CFO

Patrik M. Paulus studied Business Administration & Tax Law in Germany. He has more than 25 years of experience in Banking and Management, ten of which were as CEO of Liechtensteinische Landesbank (Schweiz) AG. He is currently enjoying success as an Entrepreneur and Co-Founder of several Startups and is Founder & Chairman of FIO Partners AG, Multi Family Office. Patrik boasts a vast knowledge of Financial and Capital Markets. By assuming the company‘s Finance authority, Patrik brings the financial skills and know-how to the firm‘s team of scientists.

DR GARY T. JENNINGS, COO

Dr. Gary T. Jennings graduated as Doctor of Biochemistry (Ph.D.) from the University of Western Australia and completed post-doctoral appointments at the U.S. National Institutes of Health and the University of Texas. He gathered experience in the biotechnology and pharmaceutical industries over 20 years. During this time he worked in numerous roles and gained extensive experience in the R&D process including discovery research, safety testing, manufacturing, regulatory, clinical trials, project management, patenting and BD&L.

PROF MARTIN F. BACHMANN, SCIENTIFIC ADVISOR

Martin F. Bachmann made a name for himself in the field of therapeutic vaccines and virus-like particles. He is Professor of Immunology at the University of Bern, Switzerland, University of Oxford, UK and visiting professor of the International Immunology Institute of Anhui University, Hefei, China. Martin Bachmann is the founder and co-founder of several biotech companies active in the field of therapeutic vaccines in humans (Saiba GmbH, HealVAX GmbH and DeepVax GmbH) and animals (Hypopet AG, Evax AG). His research has a strong focus on prophylactic and therapeutic vaccines based on virus-like particles.

Contact Us

+49 172 8895797

Berger medical Solutions GmbH

Hauptstr. 9 78253 Eigeltingen E-Mail: info@bergermedical.de

Get Started

Please contact us to get more information

de_DEDeutsch